Get the Stockscreener App
2.53
3.07%
-0.08
Acrivon Therapeutics Inc stock is traded at $2.53, with a volume of 361.09K.
It is down -3.07% in the last 24 hours and up +10.96% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$2.61
Open:
$2.63
24h Volume:
361.09K
Relative Volume:
0.50
Market Cap:
$79.83M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.9101
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+6.75%
1M Performance:
+10.96%
6M Performance:
+99.21%
1Y Performance:
-63.96%
1-Day Range:
$2.5135
$2.72
1-Week Range:
$2.38
$2.73
52-Week Range:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.53 | 82.36M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics (NASDAQ:ACRV) Downgraded to Sell Rating by Wall Street Zen - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - setenews.com
Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - moha.gov.vn
What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - setenews.com
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Insider Monkey
Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Chmn Blume-Jensen Surrenders 19,904 Of Acrivon Therapeutics Inc [ACRV] - TradingView
Citadel Advisors LLC Acquires Additional Shares in Acrivon Therapeutics Inc - GuruFocus
ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target - GuruFocus
HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments - TipRanks
Acrivon insiders report RSU tax withholding, 2.05M shares held - Stock Titan
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - MarketBeat
Will Acrivon Therapeutics Inc. stock see PE expansionWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
Research Analysts Issue Forecasts for ACRV FY2025 Earnings - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00 - Defense World
There is no way Acrivon Therapeutics Inc (ACRV) can keep these numbers up - Setenews
Acrivon Therapeutics Form 4: COO tax withholding on 613 RSU shares - Stock Titan
Acrivon Therapeutics stock rating reiterated by Citizens with $13 target - Investing.com Nigeria
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics Narrows Losses And Draws Analyst Support - Finimize
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements - TipRanks
Acrivon Therapeutics Shrinks Losses And Draws Analyst Optimism - Finimize
Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA) - The Globe and Mail
Is Acrivon Therapeutics Inc. stock supported by strong cash flowsMarket Trend Report & Community Verified Watchlist Alerts - newser.com
Acrivon Therapeutics Reports Q3 2025 Financial Results - TipRanks
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):